PGEN News and Press, Precigen Inc.

2026-02-11 09:34:06 ET Since I last reported on Precigen ( PGEN ) in early July, the stock is up 185%. A lot has transpired: the company received FDA approval for its lead asset for Recurrent Respiratory Papillomatosis (RRP).... Read the full article on Seeking Alpha ...

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis PR Newswire Independent, expert-led consensus paper, sponsored by the Recurrent Res...

2026-01-15 12:55:57 ET Precigen, Inc. (PGEN) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS in ...

Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md. , Jan. 5, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today announced that Helen Sabzevari , PhD...

2025-11-25 06:51:57 ET Introduction There have been some notable developments at Precigen, Inc. ( PGEN ) since my last look in mid-August. My Buy rating followed the FDA approval of PAPZIMEOS for adults with recurrent respiratory papillomatosis, or RRP, a rare disease. Recal...

2025-11-14 14:06:21 ET More on Vaxart, Precigen Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript The Outlook For Precigen Vaxart extends cash runway into Q2 2027 with Dynavax partnership and targets 2...

2025-11-14 11:01:33 ET Precigen, Inc. (NASDAQ: PGEN) has caught the attention of the investment community today with its bullish price action. The company’s shares have moved 30.31% on the day to $5.03. Precigen, Inc. discovers and develops the next generation of gene and cel...

2025-11-13 22:51:34 ET Precigen, Inc. (PGEN) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Steven Harasym - VP & Head of Investor Relations Helen Sabzevari - President, CEO & Director Phil Tennant - Chief Commercial Officer ...

2025-11-13 16:09:36 ET More on Precigen The Outlook For Precigen Precigen, Inc. (PGEN) H.C. Wainwright Virtual Fireside Chat Transcript Precigen Q3 Earnings Preview Precigen announces up to $125M non-dilutive financing Seeking Alpha’s Quant Rat...